Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

Emerging Roles of Cell-free Tumor DNA in Oncology The capacity to detect new cancers,
treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the …

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …

During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor
subclones harboring unique resistance mechanisms in an individual patient,–. Previous …

The MAPK pathway is one of the most commonly mutated oncogenic pathways in cancer.
Although RAS mutations are the most frequent MAPK alterations, less frequent alterations in …

Although BRAF inhibitor monotherapy yields response rates> 50% in BRAF V600-mutant
melanoma, only approximately 5% of patients with BRAF V600E colorectal cancer respond …

ATP-competitive fibroblast growth factor receptor (FGFR) kinase inhibitors, including
BGJ398 and Debio 1347, show antitumor activity in patients with intrahepatic …

Although KRAS has long been considered undruggable, direct KRAS G12C inhibitors have
shown promising initial clinical efficacy. However, the majority of patients still fail to respond …

The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

RAS genes are the most commonly mutated oncogenes in cancer, but effective therapeutic
strategies to target RAS-mutant cancers have proved elusive. A key aspect of this challenge …